Acetaminophen 325 mg tablets, packaged in a) 100-count bottle (NDC 71399-8024-01); b) 1000-count bottle (NDC 71399-8024-02), Akorn Pharma Manufactured for: Akorn Pharma, Inc., Fairfield, NJ

Recall Insight

This FDA Drug action (record #D-1352-2022) was formally reported on August 24, 2022, with the manufacturer initiating the action on August 4, 2022. It is classified under Low severity (Class III), with a current status of Terminated. Akron Pharma, Inc. is listed as the recalling firm, operating out of Fairfield, NJ. Federal records indicate 301,382 bottles units are affected, a scale large enough to require multi-state distribution tracking.

The documented reason for this recall is: Failed Tablet/Capsule Specifications: Imprint "AP 325" is missing from the tablet. Distribution data in the federal record shows the product reached: Product was distributed to 6 distributors/wholesalers who may have further distributed the product.. Distribution scope directly affects the consumer exposure window and determines whether a recall remains regional or escalates into a nationwide advisory.

To put this record in context, PlainRecalls indexes 83,949 recalls across the FDA, CPSC, NHTSA and USDA FSIS going back to 1995. Within the same product category, the database holds 6 closely related recalls, of which 5 were also issued by FDA Drug. That clustering is a signal — repeated actions in a narrow category often indicate a systemic quality-control issue, a supplier-wide contamination, or a design defect that has propagated across product lines. This recall is roughly 4 years old; older recalls can remain relevant because many units enter resale, rental, and secondary-market channels where the original warning never reaches the end user. Always cross-check the recall number against the official agency page before relying on any summary.